Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 2 General health at 4- and 8-week time-points
Groups | Blood glucose* (mg/dl) | Age at surgery (days) | Weight at surgery (g) | Weight at death (g) | Weight change (g) |
|---|---|---|---|---|---|
Saline (n = 5) | |||||
4 weeks | 444 ± 40 | 182 ± 15 | 408 ± 36 | 404 ± 28 | −4 ± 17 |
8 weeks | 421 ± 44 | 184 ± 11 | 369 ± 30 | 401 ± 30 | 33 ± 24 |
Buffer + HA/TCP (n = 6) | |||||
4 weeks | 493 ± 22 | 187 ± 12 | 398 ± 40 | 385 ± 45 | −13 ± 43 |
8 weeks | 433 ± 14 | 175 ± 20 | 394 ± 33 | 404 ± 35 | 10 ± 16 |
Low-dose rhBMP-2 + HA/TCP (n = 5) | |||||
4 weeks | 478 ± 38 | 174 ± 10 | 401 ± 15 | 407 ± 18 | 6 ± 7 |
8 weeks | 440 ± 37 | 161 ± 8 | 383 ± 60 | 383 ± 60 | 2 ± 17 |
High-dose rhBMP-2+ HA/TCP (n = 6) | |||||
4 weeks | 474 ± 44 | 176 ± 13 | 404 ± 27 | 387 ± 32 | −16 ± 22 |
8 weeks | 430 ± 27 | 177 ± 13 | 425 ± 23 | 416 ± 11 | −8 ± 18 |